Healthcare provider profile · identity verified

Mark A. Martinez, MD

Family Practice · FONTANA, CA · NPI 1538236435

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	655	232
Lisinopril	Lisinopril	392	137
Amlodipine Besylate	Amlodipine Besylate	360	135
Omeprazole	Omeprazole	312	118
Levothyroxine Sodium	Levothyroxine Sodium	307	98
Losartan Potassium	Losartan Potassium	248	99
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	235	69
Simvastatin	Simvastatin	234	88
Metformin Hcl	Metformin Hcl	219	72
Atenolol	Atenolol	209	65
Rosuvastatin Calcium	Rosuvastatin Calcium	182	71
Gabapentin	Gabapentin	181	60
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	180	69
Hydrochlorothiazide	Hydrochlorothiazide	178	59
Tamsulosin Hcl	Tamsulosin Hcl	167	60
Glipizide	Glipizide	154	54
Potassium Chloride	Potassium Chloride	151	58
Trazodone Hcl	Trazodone Hcl	132	55
Alendronate Sodium	Alendronate Sodium	122	45
Meloxicam	Meloxicam	107	47
Terazosin Hcl	Terazosin Hcl	102	39
Pantoprazole Sodium	Pantoprazole Sodium	100	35
Ibuprofen	Ibuprofen	98	40
Furosemide	Furosemide	91	36
Bisoprolol Fumarate	Bisoprolol Fumarate	87	34
Metoprolol Tartrate	Metoprolol Tartrate	87	30
Albuterol Sulfate Hfa	Albuterol Sulfate	79	58
Fluoxetine Hcl	Fluoxetine Hcl	77	25
Prednisone	Prednisone	76	66
Metformin Hcl Er	Metformin Hcl	75	38
Clopidogrel	Clopidogrel Bisulfate	71	25
Hydralazine Hcl	Hydralazine Hcl	66	23
Humulin N	Insulin Nph Human Isophane	64	23
Jardiance	Empagliflozin	60	22
Nabumetone	Nabumetone	60	23
Ezetimibe	Ezetimibe	57	22
Naproxen	Naproxen	57	15
Sertraline Hcl	Sertraline Hcl	57	20
Triamcinolone Acetonide	Triamcinolone Acetonide	53	34
Carvedilol	Carvedilol	49	17
Famotidine	Famotidine	49	23
Allopurinol	Allopurinol	48	19
Montelukast Sodium	Montelukast Sodium	48	18
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	48	15
Cephalexin	Cephalexin	47	37
Pradaxa	Dabigatran Etexilate Mesylate	47	21
Lovastatin	Lovastatin	44	15
Wixela Inhub	Fluticasone Propion/Salmeterol	43	14
Donepezil Hcl	Donepezil Hcl	40	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	40	15
Doxycycline Monohydrate	Doxycycline Monohydrate	39	30
Humulin R	Insulin Regular, Human	39	14
Finasteride	Finasteride	36	17
Humulin N Kwikpen	Insulin Nph Human Isophane	35	11
Spironolactone	Spironolactone	35	12
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	35	12
Pravastatin Sodium	Pravastatin Sodium	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	13
Alvesco	Ciclesonide	31	19
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	31	suppressed
Lactulose	Lactulose	30	suppressed
Azelastine Hcl	Azelastine Hcl	29	suppressed
Ropinirole Hcl	Ropinirole Hcl	29	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	27
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	28	11
Buspirone Hcl	Buspirone Hcl	27	11
Citalopram Hbr	Citalopram Hydrobromide	27	11
Nitroglycerin	Nitroglycerin	26	12
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	25	suppressed
Spiriva Respimat	Tiotropium Bromide	25	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	25	suppressed
Colchicine	Colchicine	23	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Mupirocin	Mupirocin	23	suppressed
Ondansetron Odt	Ondansetron	23	11
Hydrocortisone	Hydrocortisone	22	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	22	suppressed
Mirtazapine	Mirtazapine	22	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	22	suppressed
Estradiol	Estradiol	21	suppressed
Ozempic	Semaglutide	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Eliquis	Apixaban	20	suppressed
Nifedipine Er	Nifedipine	20	suppressed
Rizatriptan	Rizatriptan Benzoate	20	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	19	19
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Verapamil Er	Verapamil Hcl	19	suppressed
Azithromycin	Azithromycin	18	17
Clonidine Hcl	Clonidine Hcl	18	suppressed
Fluconazole	Fluconazole	18	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Warfarin Sodium	Warfarin Sodium	18	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	18	suppressed
Trospium Chloride	Trospium Chloride	17	suppressed
Amoxicillin	Amoxicillin	16	suppressed
Fluticasone Propionate	Fluticasone Propionate	16	suppressed
Metronidazole	Metronidazole	16	14
Valacyclovir	Valacyclovir Hcl	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Tramadol Hcl	Tramadol Hcl	15	11
Acyclovir	Acyclovir	14	suppressed
Lorazepam	Lorazepam	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	13	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	13	suppressed
Morphine Sulfate Er	Morphine Sulfate	13	suppressed
Risedronate Sodium	Risedronate Sodium	13	suppressed
Lidocaine	Lidocaine	12	suppressed
Chlorthalidone	Chlorthalidone	11	suppressed
Flunisolide	Flunisolide	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Victoza 2-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error